Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.
作者信息
Romero Carolina, Díez José-María, Gajardo Rodrigo
机构信息
Immunotherapies Unit, Global Research & Development, Bioscience R&D Scientific Innovation Office, Grifols, Barcelona 08150, Spain.
Immunotherapies Unit, Global Research & Development, Bioscience R&D Scientific Innovation Office, Grifols, Barcelona 08150, Spain.
出版信息
Lancet Infect Dis. 2022 Jan;22(1):19. doi: 10.1016/S1473-3099(21)00755-6.
Abstract
摘要
相似文献
1
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products-an update.健康供体血浆库和静脉注射免疫球蛋白产品中的抗SARS-CoV-2抗体——最新情况
Lancet Infect Dis. 2022 Jan;22(1):19. doi: 10.1016/S1473-3099(21)00755-6.
2
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.健康供体血浆库和静脉注射免疫球蛋白产品中的抗SARS-CoV-2抗体。
Lancet Infect Dis. 2021 Jun;21(6):765-766. doi: 10.1016/S1473-3099(21)00059-1. Epub 2021 Feb 16.
3
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.静脉注射免疫球蛋白制剂中的抗 SARS-CoV-2 抗体：与季节性冠状病毒、天然自身免疫反应的交叉反应性及其治疗意义。
Front Immunol. 2021 Feb 17;12:627285. doi: 10.3389/fimmu.2021.627285. eCollection 2021.
4
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies.COVID-19 疫苗接种后在静脉注射免疫球蛋白治疗的免疫神经病变中的抗体反应。
Eur J Neurol. 2022 Nov;29(11):3380-3388. doi: 10.1111/ene.15508. Epub 2022 Aug 8.
5
Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.静脉注射用免疫球蛋白由新冠康复期及新冠疫苗接种者捐献的血浆制成，对 SARS-CoV-2 具有高效中和作用。
J Infect Dis. 2021 Nov 22;224(10):1707-1711. doi: 10.1093/infdis/jiab482.
6
The presumed protective effect of IVIG against SARS-CoV-2 in inflammatory myopathy patients remains questionable.静脉注射免疫球蛋白（IVIG）对炎性肌病患者预防新型冠状病毒（SARS-CoV-2）的假定保护作用仍存在疑问。
Rheumatol Int. 2024 Feb;44(2):397-398. doi: 10.1007/s00296-023-05472-6. Epub 2023 Sep 26.
7
Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation.新冠病毒大流行前对普通感冒人类冠状病毒的免疫会引起针对 SARS-CoV-2 抗原的回忆型 IgG 反应，但无交叉中和作用。
Front Immunol. 2022 Feb 11;13:790334. doi: 10.3389/fimmu.2022.790334. eCollection 2022.
8
Modelling the concentration of anti-SARS-CoV-2 immunoglobulin G in intravenous immunoglobulin product batches.建立静脉用免疫球蛋白制品批次中抗 SARS-CoV-2 免疫球蛋白 G 浓度的模型。
PLoS One. 2021 Nov 29;16(11):e0259731. doi: 10.1371/journal.pone.0259731. eCollection 2021.
9
IgG response to spike protein of SARS-CoV-2 in healthy individuals and potential of intravenous IgG as treatment for COVID-19.健康个体对 SARS-CoV-2 刺突蛋白的 IgG 反应和静脉注射 IgG 作为 COVID-19 治疗的潜力。
Virol J. 2022 Nov 13;19(1):186. doi: 10.1186/s12985-022-01921-z.
10
Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.印度西部一家三级护理医院的经验：潜在恢复期血浆供者中 SARS-CoV-2 的血清流行率及其延迟模式分析。
Transfus Clin Biol. 2022 Feb;29(1):60-64. doi: 10.1016/j.tracli.2021.07.004. Epub 2021 Jul 22.
引用本文的文献
1
Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy.免疫球蛋白制品对接受免疫球蛋白替代治疗的抗体免疫缺陷患者季节性流感感染和严重程度的影响。
Front Immunol. 2024 Oct 22;15:1452106. doi: 10.3389/fimmu.2024.1452106. eCollection 2024.
2
Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.预防原发性抗体缺陷症患者的儿童和成人受到常见和新发病原体以及非传染性并发症的侵害。
Clin Exp Immunol. 2024 Oct 16;218(2):136-150. doi: 10.1093/cei/uxae059.
3
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
4
Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report.静脉注射免疫球蛋白治疗免疫功能低下患者的持续性 COVID-19：简要报告。
Front Immunol. 2024 Apr 19;15:1399180. doi: 10.3389/fimmu.2024.1399180. eCollection 2024.
5
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment.乙酰胆碱受体抗体阳性的全身性重症肌无力：治疗指南。
Eur J Neurol. 2024 May;31(5):e16229. doi: 10.1111/ene.16229. Epub 2024 Feb 6.
6
Intravenous immunoglobulin for treatment of hospitalized COVID-19 patients: an evidence mapping and meta-analysis.静脉注射免疫球蛋白治疗住院 COVID-19 患者：证据图谱和荟萃分析。
Inflammopharmacology. 2024 Feb;32(1):335-354. doi: 10.1007/s10787-023-01398-4. Epub 2023 Dec 14.
7
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.特卡昔单抗可损害经大量预处理的骨髓瘤患者的体液免疫：免疫球蛋白补充的重要性。
Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658.
8
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.抗 BCMA 双特异性抗体治疗多发性骨髓瘤患者中，使用 IVIg 与严重感染风险降低 10 倍相关。
Blood Cancer Discov. 2023 Nov 1;4(6):440-451. doi: 10.1158/2643-3230.BCD-23-0049.
9
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin.评估接受静脉注射免疫球蛋白治疗的特发性炎性肌病患者对 SARS-CoV-2 的抗体水平。
Rheumatol Int. 2023 Sep;43(9):1629-1636. doi: 10.1007/s00296-023-05350-1. Epub 2023 Jun 27.
10
T cell immunity following COVID-19 vaccination in adult patients with primary antibody deficiency - a 22-month follow-up.COVID-19 疫苗接种后成人原发性抗体缺陷患者的 T 细胞免疫 - 22 个月随访。
Front Immunol. 2023 May 9;14:1146500. doi: 10.3389/fimmu.2023.1146500. eCollection 2023.
本文引用的文献
1
Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis.静脉注射免疫球蛋白（IVIG）治疗 2019 年冠状病毒病（COVID-19）的疗效：一项荟萃分析。
Int Immunopharmacol. 2021 Jul;96:107732. doi: 10.1016/j.intimp.2021.107732. Epub 2021 Apr 30.
2
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.健康供体血浆库和静脉注射免疫球蛋白产品中的抗SARS-CoV-2抗体。
Lancet Infect Dis. 2021 Jun;21(6):765-766. doi: 10.1016/S1473-3099(21)00059-1. Epub 2021 Feb 16.
3
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens.目前可用的静脉用免疫球蛋白含有针对严重急性呼吸综合征冠状病毒 2 抗原的抗体。
Immunotherapy. 2020 Jun;12(8):571-576. doi: 10.2217/imt-2020-0095. Epub 2020 May 12.
Zotero 插件